Radiologic–Pathologic correlation of tumors in lung cancer.

Amir Ali*

Department of cancer, University of Islamic azad, Iraq

Abstract

The radiologic-pathologic correlation of tumors in lung cancer is a critical component of the diagnostic and treatment process for this disease. In this process, radiologic imaging techniques such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and Positron Emission Tomography (PET) are used to identify suspicious lesions or masses in the lungs. Once a suspicious lesion is identified, a biopsy is taken to confirm the diagnosis of lung cancer and determine the specific type of cancer. The biopsy can be performed using various methods, such as a needle biopsy, bronchoscopy, or surgery. The pathology report from the biopsy is then compared with the radiologic imaging findings to correlate the radiologic features of the lesion with the histologic characteristics of the tumor.

Keywords: Positron emission tomography, Computed tomography, Lung cancer.

Introduction

Radiologic-pathologic correlation allows for a more accurate diagnosis and staging of lung cancer, which is critical for determining the most appropriate treatment plan. For example, the presence of certain radiologic features, such as the size and location of the tumor, can affect the choice between surgery or radiation therapy as the primary treatment modality. In addition, radiologic-pathologic correlation can provide valuable information on the prognosis of the patient, as certain radiologic and histologic characteristics of the tumor can be associated with more aggressive or less responsive tumors. Overall, the radiologic-pathologic correlation of tumors in lung cancer is an essential step in the diagnostic and treatment process, allowing for more accurate diagnosis, staging, and treatment planning for patients with this disease [1].

Lung cancer is a malignant disease that develops when the cells of the lung grow abnormally and form tumors. There are two main types of lung cancer: Non-small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). The diagnosis and treatment of lung cancer typically involve a combination of radiologic and pathologic assessments to accurately identify the type, location, and extent of the tumor [2].

Radiologic Imaging

Radiologic imaging techniques are essential in the diagnosis and staging of lung cancer. Imaging tests such as chest X-rays, Computed Tomography (CT) scans, Magnetic Resonance Imaging (MRI), and Positron Emission Tomography (PET) scans can provide valuable information about the size, location, and spread of the tumor. Chest X-rays are often used as a first-line imaging test for lung cancer, but they are not very sensitive or specific. CT scans are more accurate and can provide detailed images of the lungs and surrounding tissues, helping to identify the location and extent of the tumor. MRI scans are useful for evaluating the involvement of the chest wall, mediastinum, and diaphragm, but they are not as commonly used as CT scans. PET scans are often used in combination with CT scans to provide information about the metabolic activity of the tumor and help differentiate between malignant and benign lesions.

Pathologic Assessment

Pathologic assessment involves the examination of tissue samples to identify the type and extent of the cancer. The most common methods of obtaining tissue samples for lung cancer include bronchoscopy, needle biopsy, and surgical resection.

Bronchoscopy involves the insertion of a flexible tube (bronchoscope) into the airways to obtain a biopsy of the tumor. Needle biopsy involves the insertion of a needle through the chest wall to obtain a sample of the tumor. Surgical resection involves the removal of the tumor through a surgical procedure. The tissue samples obtained through these methods are sent to a pathology laboratory, where they are examined under a microscope by a pathologist. The pathologist can identify the type of cancer, its stage, and its characteristics (such as the presence of certain genetic mutations) that can guide treatment decisions [3].

Radiologic-Pathologic Correlation

Radiologic-pathologic correlation involves the integration of radiologic and pathologic findings to accurately diagnose and stage lung cancer. The combination of these two approaches provides a more comprehensive understanding of the tumor, its location, and its extent. For example, a CT scan may show

***Correspondence to:** Amir Ali, Department of cancer, University of Islamic azad, Iraq, E-mail: amir@ali.ac.ir

***Received:** 23-Feb-2023, Manuscript No. AACCR-23-94619; **Editor assigned:** 27-Feb-2023, PreQC No. AACCR-23-94619 (PQ); **Reviewed:** 14-Mar-2023, QC No. AACCR-23-94619; **Revised:** 20-Mar-2023, Manuscript No. AACCR-23-94619 (R); **Published:** 28-Mar-2023, DOI:10.35841/aaccr-6.1.137*

***Citation:** Ali A. Radiologic–Pathologic correlation of tumors in lung cancer. J Can Clinical Res. 2023;6(1):137*

a suspicious mass in the lung, but a biopsy may be needed to confirm that it is cancerous. Once the biopsy results are available, the radiologist can use the CT scan to determine the size and location of the tumor and assess whether it has spread to nearby lymph nodes or other organs. Radiologic-pathologic correlation is particularly important in the staging of lung cancer, which involves determining the extent of the cancer and whether it has spread beyond the lung. Staging is important because it helps guide treatment decisions and predicts outcomes [4].

The most commonly used staging system for lung cancer is the TNM system, which stands for tumor, node, and metastasis. The TNM system uses information from both radiologic and pathologic assessments to determine the extent of the cancer. Tumor (T) describes the size and location of the primary tumor. Radiologic imaging is used to determine the size and location of the tumor, while pathologic assessment is used to determine the histologic type of the tumor. Node (N) describes the involvement of nearby lymph nodes. Radiologic imaging can detect enlarged lymph nodes, but pathologic assessment is needed to confirm whether the lymph nodes contain cancer cells. Metastasis (M) describes the spread of the cancer to other organs. Radiologic imaging can detect the presence of metastases, but pathologic assessment is needed to confirm, the most common histological subtypes of lung cancer are Non-Small Cell Lung Carcinoma (NSCLC) and Small Cell Lung Carcinoma (SCLC), each with its unique imaging and pathological features. NSCLC typically presents as a solitary mass or nodule with irregular margins, whereas SCLC tends to be more centrally located with a diffuse infiltrative pattern. Radiologic-pathologic correlation is also essential in assessing treatment response and identifying recurrence or metastasis. Imaging techniques such as CT and PET can be used to monitor changes in tumor size and metabolic activity following treatment, but histopathological evaluation is necessary to confirm the presence of residual disease or new tumor growth. Overall, radiologic-pathologic correlation is a crucial tool in the diagnosis and management of lung cancer. By combining imaging and histopathological information, clinicians can make more informed treatment decisions and improve patient outcomes [5].

Conclusion

In conclusion, radiologic-pathologic correlation plays a critical role in the diagnosis and management of lung cancer. By integrating imaging findings with histopathological characteristics, clinicians can more accurately identify the type and stage of the tumor, which can guide treatment decisions and improve patient outcomes. Computed Tomography (CT) is the primary imaging modality used in the evaluation of lung tumors, but other imaging techniques such as Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), and ultrasound can also provide valuable information.

References

1. Cho A, Hur J, Kang WJ, et al. Usefulness of FDG PET/CT in determining benign from malignant endobronchial obstruction. Eur Radiol. 2011;21:1077-87.
2. Maziak DE, Todd TR, Keshavjee SH, et al. Adenoid cystic carcinoma of the airway: thirty-two-year experience. J Thorac Cardiovasc Surg. 1996;112(6):1522-32.
3. Regnard JF, Fourquier P, Levasseur P. Results and prognostic factors in resections of primary tracheal tumors: a multicenter retrospective study. J Thorac Cardiovasc Surg. 1996;111(4):808-14.
4. Dean CW, Speckman JM, Russo JJ. AIRP best cases in radiologic-pathologic correlation: adenoid cystic carcinoma of the trachea. Radiographics. 2011;31(5):1443-7.
5. Li X, Zhang W, Wu X, et al. Mucoepidermoid carcinoma of the lung: common findings and unusual appearances on CT. Clin Imaging. 2012;36(1):8-13.

Citation: *Ali A. Radiologic–Pathologic correlation of tumors in lung cancer. J Can Clinical Res. 2023;6(1):137*